USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS

The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD. La présente invention concerne l'utilisation de méthylnaltrexone, ou d'un sel de celle-ci, et...

Full description

Saved in:
Bibliographic Details
Main Authors DENG, XiaoJun Nicole, JO SIU, William J, HEIMANSON, Zeev, ISRAEL, Robert J, JOHNSON, Lorin K
Format Patent
LanguageEnglish
French
Published 10.12.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD. La présente invention concerne l'utilisation de méthylnaltrexone, ou d'un sel de celle-ci, et de rifaximine pour le traitement d'une perméabilité intestinale accrue, ou d'un trouble associé, par exemple, la SHNA ou la NAFLD.
Bibliography:Application Number: WO2020EP65374